Trials / Unknown
UnknownNCT00022893
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma
Retreatment Study of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti-B1 Antibody.
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Corixa Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to enable retreatment with Iodine-131 Anti-B1 Antibody therapy for patients with non-Hodgkin's lymphoma (NHL) who previously responded (PR, CCR, or CR) for at least 3 months to Iodine-131 Anti-B1 Antibody therapy.
Detailed description
The endpoints of the study are to determine the response rate, complete response rate, duration of response, time to progression, time-to-treatment failure, safety, and survival following Iodine-131 Anti-B1 Antibody therapy in patients with NHL who previously responded (PR, CCR, or CR) with a duration of response of at least 3 months to Iodine-131 Anti-B1 Antibody therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iodine-131 Anti-B1 Antibody |
Timeline
- First posted
- 2001-08-17
- Last updated
- 2005-06-24
Locations
5 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT00022893. Inclusion in this directory is not an endorsement.